BAMS
PBYI icon

Bellevue Asset Management (Switzerland)’s Puma Biotechnology PBYI Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-3,000
Closed -$350K – 136
2015
Q2 		$350K Hold
3,000
– – 0.05% 131
2015
Q1 		$708K Buy
+3,000
New +$641K 0.1% 125

Other funds holding PBYI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s PBYI Position: Q3 2015 in Review

Bellevue Asset Management (Switzerland) sold out of Puma Biotechnology (PBYI) in Q3 2015, closing a stake of 3,000 shares — an estimated $350K sold.

Bellevue Asset Management (Switzerland) first reported a position in PBYI in Q1 2015 and held it in 2 quarters. The position peaked at $708K in Q1 2015. 163 funds tracked by Wall St. Rank hold PBYI as of Q3 2015.

  • Bellevue Asset Management (Switzerland) reported no remaining Puma Biotechnology position as of Q3 2015 after selling out during the quarter.
  • Bellevue Asset Management (Switzerland) sold 3,000 Puma Biotechnology shares in Q3 2015, an estimated $350K.
  • Bellevue Asset Management (Switzerland) first reported a position in Puma Biotechnology in Q1 2015 and held it in 2 quarters.
  • Bellevue Asset Management (Switzerland)'s Puma Biotechnology position peaked at $708K in Q1 2015.
  • 163 funds tracked by Wall St. Rank held Puma Biotechnology as of Q3 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q3 2015, filed 12 Nov 2015.